G protein-coupled receptor oligomerization and brain integration: focus on adenosinergic transmission

Brain Research
Francisco CiruelaCarla I Tasca

Abstract

The control of glutamatergic corticostriatal transmission is essential for the induction and expression of plasticity mechanisms in the striatum, a phenomenon thickly regulated by G protein-coupled receptors (GPCRs). Interestingly, in addition to dopamine receptors, adenosine and metabotropic glutamate receptors also play a key role in striatal functioning. The existence of a supramolecular organization (i.e. oligomer) containing dopamine, adenosine and metabotropic glutamate receptors in the striatal neurons is now being widely accepted by the scientific community. Indeed, these oligomers may enhance the diversity and performance by which extracellular striatal signals are transferred to the G-proteins in the process of receptor transduction, and also may allow unpredictable receptor-receptor allosteric regulations. Overall, here we want to review how formations of adenosine, dopamine and metabotropic glutamate receptors-containing oligomers impinge into striatal functioning in both normal and pathological conditions. This article is part of a Special Issue entitled: Brain Integration.

References

Jan 1, 1985·Annual Review of Neuroscience·S H Snyder
Jun 3, 1986·Biochemistry·G L PetersonM I Schimerlik
Jan 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·S AvissarM Sokolovsky
Mar 15, 1994·European Journal of Pharmacology·G Y NgB F O'Dowd
Apr 1, 1995·Pharmacology & Toxicology·B B Fredholm
Jan 1, 1995·Neuropharmacology·J P Pin, R Duvoisin
Jan 1, 1994·Annual Review of Neuroscience·M Hollmann, S Heinemann
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C A SalvatoreR G Johnson
Feb 1, 1996·Brain : a Journal of Neurology·P P Pramstaller, C D Marsden
Oct 3, 1996·Biochemical and Biophysical Research Communications·G Y NgS R George
Jan 19, 1999·FEBS Letters·P ZawarynskiS R George
Mar 12, 1999·Neuroscience and Biobehavioral Reviews·A Nehlig
Jul 13, 2000·Proceedings of the National Academy of Sciences of the United States of America·S GinésR Franco
Apr 12, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·J Yelnik
Aug 22, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergi FerréFrancisco Ciruela
Oct 2, 2002·Journal of Neurochemistry·Stéphane Le CromPhilippe Vernier
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Akinori NishiPaul Greengard
Feb 1, 2003·Neuropharmacology·P GubelliniP Calabresi
Sep 10, 2003·The Journal of Physiology·Masahiro KimuraTomoyuki Takahashi
Nov 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kimberly A MooreDietmar Schmitz
Mar 25, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roberto CoccurelloMarianne Amalric
May 26, 2004·The Journal of Biological Chemistry·Samuel P LeeSusan R George
Jun 16, 2004·Parkinsonism & Related Disorders·Sergi FerréAmina Woods
Nov 11, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anil KachrooMichael A Schwarzschild
Feb 17, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Francisco CiruelaRafael Franco
Mar 7, 2006·Nature Reviews. Drug Discovery·Kenneth A Jacobson, Zhan-Guo Gao

❮ Previous
Next ❯

Citations

Oct 10, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kjell FuxeLuigi F Agnati
Jun 20, 2014·Purinergic Signalling·Izaskun Villar-MenéndezMarta Barrachina
Jan 6, 2015·Behavioural Brain Research·Leandra C ConstantinoCarla I Tasca
May 3, 2016·Expert Opinion on Drug Discovery·Antoni CortésVicent Casadó
Oct 5, 2016·Aging and Disease·Débora LanznasterCarla I Tasca
May 4, 2016·Therapeutic Advances in Psychopharmacology·Dasiel O Borroto-EscuelaKjell Fuxe
Apr 18, 2018·Current Neuropharmacology·David Agustín León-NavarroMairena Martín
Apr 14, 2016·Biochemical Society Transactions·Verònica Casadó-AngueraVicent Casadó
Nov 22, 2018·Frontiers in Cellular Neuroscience·Carla I TascaFrancisco Ciruela
May 14, 2020·Neural Plasticity·Ella E BauerPeter J Clark
Feb 29, 2020·Pharmacology & Therapeutics·Ana Raquel SantiagoAntónio Francisco Ambrósio
Feb 20, 2021·European Journal of Pharmacology·Zi-Fan MaiChu-Hua Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.